ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review

ReNeuron Group Plc (RENE) - Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH81745FSA
  • |
  • Pages: 54
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

ReNeuron Group Plc (RENE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ReNeuron Group Plc (ReNeuron) is a clinical-stage stem cell company which develops innovative stem cell therapies targeting areas of significant unmet medical need. The company's therapeutic candidates in clinical development are focused at treating motor disability as a result of stroke, critical limb ischaemia and the blindness-causing disease retinitis pigmentosa. Its lead CTX stem cell therapeutic candidate is a therapy for treating patients left disabled by a stroke. ReNeuron utilizes its exclusive stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be administered off-the-shelf to any fit patient without the requirement for additional immunosuppressive drug treatments. ReNeuron is headquartered in Pencoed, Bridgend, the UK.

ReNeuron Group Plc Key Recent Developments

Jul 12,2018: ReNeuron: Preliminary results for the year ended 31 March 2018

Apr 19,2018: ReNeuron: Wins grant for retinal cell therapy development

Apr 10,2018: Appointment Of US-Based Chief Medical Officer

Apr 10,2018: ReNeuron: Appointment of US-based Chief Medical Officer

Mar 26,2018: ReNeuron Group: Product Development Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

ReNeuron Group Plc-Key Facts 6

ReNeuron Group Plc-Key Employees 7

ReNeuron Group Plc-Key Employee Biographies 8

ReNeuron Group Plc-Major Products and Services 9

ReNeuron Group Plc-History 10

ReNeuron Group Plc-Company Statement 13

ReNeuron Group Plc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 15

Company Overview 15

ReNeuron Group Plc-Business Description 16

ReNeuron Group Plc-Corporate Strategy 17

ReNeuron Group Plc-SWOT Analysis 18

SWOT Analysis-Overview 18

ReNeuron Group Plc-Strengths 18

ReNeuron Group Plc-Weaknesses 19

ReNeuron Group Plc-Opportunities 20

ReNeuron Group Plc-Threats 21

ReNeuron Group Plc-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

ReNeuron Group Plc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Jul 12, 2018: ReNeuron: Preliminary results for the year ended 31 March 2018 32

Apr 19, 2018: ReNeuron: Wins grant for retinal cell therapy development 38

Apr 10, 2018: ReNeuron: Appointment of US-based Chief Medical Officer 39

Apr 10, 2018: Appointment Of US-Based Chief Medical Officer 40

Mar 26, 2018: ReNeuron Group: Product Development Update 41

Feb 14, 2018: The Alliance for Regenerative Medicine Announces Initial Slate of Presenting Companies at the Sixth Annual Cell & Gene Therapy Investor Day 43

Dec 14, 2017: ReNeuron Group: Interim Results for the six months ended 30 September 2017 44

Dec 08, 2017: ReNeuron opens US office 47

Oct 27, 2017: ReNeuron Group: ReNeuron wins further UK grant to advance its exosome therapy platform 48

Sep 01, 2017: ReNeuron Group: Non-executive Director Appointment 49

Section 6-Appendix 50

Methodology 50

Ratio Definitions 50

About GlobalData 54

Contact Us 54

Disclaimer 54

List of Figures

ReNeuron Group Plc, Performance Chart (2014-2018) 26

ReNeuron Group Plc, Ratio Charts 28

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30

List of Tables

ReNeuron Group Plc, Key Facts 6

ReNeuron Group Plc, Key Employees 7

ReNeuron Group Plc, Key Employee Biographies 8

ReNeuron Group Plc, Major Products and Services 9

ReNeuron Group Plc, History 10

ReNeuron Group Plc, Subsidiaries 14

ReNeuron Group Plc, Key Competitors 22

ReNeuron Group Plc, Ratios based on current share price 23

ReNeuron Group Plc, Annual Ratios 24

ReNeuron Group Plc, Annual Ratios (Cont...1) 25

ReNeuron Group Plc, Interim Ratios 27

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

ReNeuron Group Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

ReNeuron Group Plc, Recent Deals Summary 31

Currency Codes 50

Capital Market Ratios 50

Equity Ratios 51

Profitability Ratios 51

Cost Ratios 52

Liquidity Ratios 52

Leverage Ratios 53

Efficiency Ratios 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

ViaCord LLC

Geron Corp

CovalAb UK Ltd

CBR Systems Inc

Biostatus Ltd

Avita Medical Ltd

ReNeuron Group Plc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8985
Site License
USD 250 INR 17970
Corporate User License
USD 375 INR 26955

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com